21 studies found for:    Emtricitabine / Rilpivirine / Tenofovir disoproxil fumarate OR Complera[TREATMENT] AND HIV [CONDITION]
Show Display Options
Download search resultsDownload the search results for:
Emtricitabine / Rilpivirine / Tenofovir disoproxil fumarate OR Complera[TREATMENT] AND HIV [CONDITION] (21 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Completed
Has Results
Study to Evaluate Switching From a Regimen Consisting of the Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (STR) to the Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate STR
Condition: HIV-1 Infection
Intervention: Drug: FTC/RPV/TDF
2 Recruiting FTC/RPV/TDF on T-Cell Activation, CD4 Cell Count, Inflammatory Biomarkers and Viral Reservoir
Condition: HIV-1 Infection
Intervention: Drug: Emtricitabine/rilpivirine/tenofovir disoproxil fumarate
3 Completed
Has Results
Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
Condition: HIV-1 Infection
Interventions: Drug: FTC/RPV/TDF;   Drug: EFV/FTC/TDF
4 Active, not recruiting
Has Results
Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF
Condition: HIV-1 Infection
Interventions: Drug: FTC/RPV/TDF;   Drug: PI;   Drug: RTV;   Drug: NRTIs
5 Recruiting Assessing Short and Long Term Compliance With Caloric Intake in HIV Positive Women Taking Complera
Condition: HIV-1 Infection
Intervention:
6 Recruiting A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment
Condition: Human Immunodeficiency Virus-type 1 Infection
Interventions: Drug: Rilpivirine;   Drug: Efavirenz;   Drug: Tenofovir disoproxil fumarate;   Drug: Emtricitabine
7 Not yet recruiting Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir
Condition: HIV
Intervention: Drug: Rilpivirine/Emtricitabine/Tenofovir
8 Active, not recruiting A Pilot Study to Assess the Feasibility of Switching, Individuals Receiving Atripla With Continuing Central Nervous System (CNS) Toxicity, to a Fixed Dose Combination of Tenofovir/Emtricitabine/Rilpivirine
Condition: HIV
Intervention: Drug: tenofovir/emtricitabine/rilpivirine
9 Active, not recruiting Phase 3b Open Label Study to Evaluate Switching From Regimens Consisting of a Non-nucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV 1 Infected Patients
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: Stribild;   Drug: TVD;   Drug: NNRTI
10 Not yet recruiting Switching From Efavirenz/Atripla to Rilpivirine Among Patients With Neurocognitive or Neuropsychological Side Effects
Conditions: Impaired Cognition;   Depression/Anxiety;   Poor Quality Sleep;   Quality of Life;   HIV-1 Infection
Interventions: Drug: Immediate switch to TDF/FTC/RPV;   Drug: Switch to TDF/FTC/RPV after 12 weeks
11 Not yet recruiting Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis
Condition: Human Immunodeficiency Virus (HIV)
Interventions: Drug: Rilpivirine;   Drug: Placebo
12 Completed
Has Results
TMC278-TiDP6-C209: A Clinical Trial in Treatment Naive HIV-1 Patients Comparing TMC278 to Efavirenz in Combination With Tenofovir + Emtricitabine.
Conditions: HIV Infections;   HIV-1;   Human Immunodeficiency Virus Type 1
Interventions: Drug: TMC278;   Drug: efavirenz
13 Completed Pharmacokinetics of Tenofovir and Tenofovir-diphosphate, Emtricitabine and Emtricitabine-triphosphate, and Rilpivirine Once Daily Over 14 Days Following Drug Intake Cessation in Healthy Volunteers
Condition: HIV
Intervention: Drug: Eviplera®
14 Active, not recruiting A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Efficacy of TMC278 in Human Immunodeficiency Virus Infected Adolescents
Condition: Human Immuno Deficiency (HIV) Infections
Interventions: Drug: TMC278;   Drug: Zidovudine;   Drug: Abacavir;   Drug: Tenofovir disoproxil fumarate;   Drug: Lamivudine;   Drug: Emtricitabine
15 Recruiting Safety, Tolerability,and Adherence to Co-formulated Tenofovir-emtricitabine-rilpivirine Used as HIV Nonoccupational Post-exposure Prophylaxis in Men Who Have Sex With Men.
Condition: HIV Nonoccupational Post-exposure Prophylaxis in Men Who Have Sex With Men
Intervention: Drug: Eviplera = emtricitabine 200mg, rilpivirine 25mg, tenofovir 245mg
16 Completed
Has Results
A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines
Condition: Human Immunodeficiency Virus Type 1
Interventions: Drug: TMC278 25 mg;   Drug: TMC278 75 mg;   Drug: TMC278 150 mg;   Drug: Efavirenz;   Drug: Non-nucleoside reverse transcriptase inhibitor (NRTIs)
17 Active, not recruiting Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK1265744 10 mg;   Drug: GSK1265744 30 mg;   Drug: GSK1265744 60 mg;   Drug: Efavirenz 600 mg;   Drug: Rilpivirine 25 mg;   Drug: Placebo;   Drug: Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC)
18 Recruiting Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF
Condition: HIV-1 Infection
Interventions: Drug: FTC/TDF;   Drug: F/TAF;   Drug: Allowed third antiretroviral agent;   Drug: Placebo to match FTC/TDF;   Drug: Placebo to match F/TAF
19 Recruiting 4 Consecutive Days on Treatment Followed by 3 Days Off Treatment, in HIV Patients
Condition: HIV-1 Infection
Intervention: Drug: Four consecutive days on treatment and 3 days off
20 Recruiting Hepatic Safety of Eviplera® in HIV/Hepatitis C (HCV)-Coinfected Patients Without HCV Treatment in the "The HEPAVIR HEPATIC SAFETY Cohort."
Condition: Human Immunodeficiency Virus (HIV) Hepatitis C Virus (HCV) Coinfected Subjects
Intervention:

Previous Page Studies Shown (1-20) Next Page (21-21) Show next page of results
Indicates status has not been verified in more than two years